2026 · 2nd Quarter (Apr 1 - June 30)

NOVO NORDISK INC.

Filed by NOVO NORDISK INC..

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: Not reported
Expenses: $1,300,000.00
Registrant: NOVO NORDISK INC.
Client: NOVO NORDISK INC.
Filing UUID: db59d922-211e-408b-8d17-452784128764
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding.

Literal federal measure citations: S. 150

BUD · Budget/Appropriations

Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill.

MMM · Medicare/Medicaid

Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around drug pricing.

CPT · Copyright/Patent/Trademark

S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding.

Literal federal measure citations: S. 150

TAX · Taxation/Internal Revenue Code

International and corporate tax issues.

TAR · Tariff (miscellaneous tariff bills)

Tariffs and trade policy.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.